AMARIN CORP PLC\UK Deferred Tax Liabilities, Gross
AMARIN CORP PLC\UK (AMRN) had Deferred Tax Liabilities, Gross of $4.81 million as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Income Taxes › Deferred Tax Assets, Net
us-gaap:DeferredIncomeTaxLiabilities · last filed 2026-03-02
- 2025-12-31: Deferred Tax Liabilities, Gross $4.81M.
- 2024-12-31: Deferred Tax Liabilities, Gross $4.36M.
- 2023-12-31: Deferred Tax Liabilities, Gross $4.52M.
- 2022-12-31: Deferred Tax Liabilities, Gross $4.94M.
| Period end | Deferred Tax Liabilities, Gross | Deferred Tax Liabilities, Gross as first filed |
|---|---|---|
| 2025-12-31 | $4.81M 10-K · filed 2026-03-02 | |
| 2024-12-31 | $4.36M 10-K · filed 2026-03-02 | |
| 2023-12-31 | $4.52M 10-K · filed 2025-03-12 | |
| 2022-12-31 | $4.94M 10-K · filed 2024-02-29 | |
| 2021-12-31 | $5.05M 10-K · filed 2023-03-01 | |
| 2020-12-31 | $4.19M 10-K · filed 2022-03-01 | |
| 2019-12-31 | $4.80M 10-K · filed 2021-02-25 | |
| 2018-12-31 | $1.51M 10-K · filed 2020-02-25 | |
| 2017-12-31 | $1.74M 10-K · filed 2019-02-27 | |
| 2016-12-31 | $1.80M 10-K · filed 2018-02-27 | $1.05M 10-K · filed 2017-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |